Drug profile · INN
elapegademase-lvlr
REVCOVI
elapegademase-lvlr (REVCOVI) is a 2'-deoxyadenosine hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — elapegademase-lvlr
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
elapegademase-lvlr (REVCOVI) is a 2'-deoxyadenosine hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
2'-deoxyadenosine hydrolytic enzyme
Primary target: 2'-deoxyadenosine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is elapegademase-lvlr?
elapegademase-lvlr (REVCOVI) is a 2'-deoxyadenosine hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for elapegademase-lvlr?
REVCOVI is a marketed brand name for elapegademase-lvlr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elapegademase-lvlr?
elapegademase-lvlr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.